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Dr Vinay Badhwar (Pittsburgh, Pa). This is another fine
contribution to guide surgical decision making when faced with
atrial fibrillation (AF) at the time of mitral valve operations.
This retrospective analysis of prospectively collected data of 208
propensity-matched pairs of patients receiving mitral surgery
and the Cox-MAZE IV procedure when AF was present versus
mitral surgery alone when it was not. This important work pro-
vides us with clear level II(a) evidence that the addition of a
concomitant Cox-maze IV procedure during mitral surgery is
safe and not associated with any negative effect on short- or
midterm outcomes.
Consistent with the recent literature, this study’s Cox propor-
tional hazards regression comparison of 236 unmatched patients
with AF presenting for mitral surgery who received the maze
procedure versus 75 who did not, also confirms clear short- and
midterm survival advantage associated with the maze operation.
I have 3 questions to help us interpret this important data, which
I will ask in sequence giving you time to respond.
Number 1: In the 75 patients with AFwho did not undergomaze
procedure, how many of these were nonparoxysmal?
Dr Niv Ad (Falls Church, Va). That is an excellent question.
Two groups of untreated and treated patients actually came, the
same distribution of the type of AF.
Dr Badhwar. Number 2: These 75 patients were actually older,
had lower ejection fractions, and a higher preoperative risk profile
as measured by European System for Cardiac Operative Risk Eval-
uation (EuroSCORE). Given the cohort size difference in the maze
versus no maze regression analyses, bias included, how do you
reconcile the influence of preoperative risk on the interpretation
of the Kaplan-Meier survival curves? In other words, tomorrow
when we are faced with an elderly high-risk patient with a low
ejection fraction presenting for mitral surgery, are you convinced
that this data provides us the support that the addition of a maze
operation at the time of mitral replacement or repair is warranted?
Dr Ad. Well, that sums everything. It is the decision making.
We are working a lot on understanding decision making related
to surgical ablation of AF. We created a clinical algorithm of
risk scores combined with surgeon’s experience in surgical abla-
tion to test and better understand what influences the decision
the most. An upcoming publication will cover this.
To put it simply, what type of concomitant problem the patient
has and how sick the patient is. In other words, what do we think in
our ownminds that the 5-year survival of the patient is going to be?
Also, how complex is the surgery going to be if we add the surgical
ablation procedure? In other words, how long does it take you to
add the maze procedure to a mitral valve replacement or repair
(it doesn’t take long if you are doing it a lot)? I am looking all1434 The Journal of Thoracic and Cardiovascular Surthe time at right ventricle function. If the right ventricle is rela-
tively dysfunctional, then my threshold to perform the procedure
is going to be very low.
Dr Badhwar.We know that the effective technical performance
of the Cox-maze IVoperation relies on one’s knowledge of energy
sources and the lesion set; in other words, experience. So as a maze
procedure expert in your institution, what proportion of those 311
cases presenting for mitral surgery with AF did you do person-
ally—approximately 76%? Expecting my hypothesis might be
close, perhaps this is simply a provocative way of asking what
role our professional societies and the device industry should
play in surgical education of the maze procedure now that global
evidence continues to mount as to longitudinal outcome benefits
associated with concomitant surgical ablation?
Dr Ad. I think it is an excellent point, but I think the biggest
question is not my personal contribution to this series. I can give
you the numbers: I did 175 out of 236 ablations and only 4 out
of 75 in the untreated group. Clearly I am more aggressive in
applying the maze procedure in my patients.
I believe that the biggest message is how can someone with
more experience within a group of surgeons—and this applies to
any type of surgery not just for AF—can convey a solid message
to their other partners. There are 2 different types of surgeons:
those who are more experienced than you are and they know and
have seen everything before you and, therefore, it is very difficult
to change them, and those who are younger and reluctant to
increase the complexity of the procedure and by so doing may in-
crease morbidity.
My role right now is to convey a message that it is safe and can
be done appropriately, it can be staged, and maybe I can assist
them in part of the cases so younger surgeons—as well as more
veteran ones who are willing to learn—are shown how to do it
appropriately and will apply the procedure to many more eligible
patients.
Dr Badhwar. So that this data provides us with a call to action
to further promote surgical education of surgical ablation?
Dr Ad. Yes.
Dr Patrick M. McCarthy (Chicago, Ill). I have some short,
specific questions. How did you handle the left atrial appendage
in the 2 groups, and do you know the late stroke risk in the groups?
DrAd. For the open cases, until recently (I don’t have the cutoff
dates) I think in a little more than 210 patients the appendage was
basically cut and oversewn. There are not any other devices. Lately
we started to use with much success the AtriClip (AtriCure, Inc,
West Chester, Ohio), which we are very happy with. These are
the 2 major modes.
As for the AF group, unfortunately, and this is something we are
working hard on, only in 4 out of 75 patients the appendage was
managed. This is a gap that we have to close, and I think that
now it is clear that no patients with AF, whether they have AF sur-
gery or not, should leave the operating room with the left atrial
appendage not being closed. We don’t have the data about the
late stroke rate for the untreated group.
DrMcCarthy.Another quick question: How do you handle dis-
continuing warfarin and do you use scores like CHADS, or CHA2
DS2 VASc to help decide?
DrAd.We put all patients, unless there is a contraindication, on
warfarin. Our time to stop warfarin is 6 months, because I thinkgery c December 2013
Ad et al Acquired Cardiovascular Diseasethere is a lot of background noise around 3months, and if you try to
stop it at 3 months it is kind of unrealistic. Patients’ antiarrhythmia
drugs are being stopped at 3 months if they are in sinus rhythm, and
they are being monitored at 6 months, and if the patients are found
to be in sinus rhythm, we perform echocardiography, and if the
appendage is eliminated and there is no smoke in the left atrium,
in other words, the flow seems to be okay regardless of A-waves
in the left atrium, we stop the warfarin. We don’t really look
into the CHADS score, and we actually published an excellent
article a while back that showed that the CHADS score is irrelevant
in this subgroup of patients.
Dr A. Marc Gillinov (Cleveland, Ohio). Everybody in this se-
ries had a biatrial lesion set, a Cox-maze III or IV. What would you
say to the surgeonwho says, okay, I am going to perform ablations,
but I am only going to do pulmonary vein isolation?
Dr Ad. I don’t think it’s a good idea, even in the paroxysmal
setup, because we don’t know enough about the effects of parox-
ysmal AF on the other parts of the atrium; for example, can it beThe Journal of Thoracic and Caroriginated outside the pulmonary veins or not? We know it’s a
long discussion. So I would definitely recommend considering
the biatrial Cox-maze lesion set in all patients unless there are is-
sues that should be dealt with to avoid it.
Dr Harold G. Roberts (Lauderdale Lakes, Fla). Were any of
the failures perhaps related to assessment of left atrial size?
Have you found that if you do have a large left atrium that reduc-
tion has any role in increasing the success?
Dr Ad. In our multivariate models we never found atrial size as
an independent predictor in a multivariate model for failure. The
only predictor for failure in our multivariate model that is consis-
tent is duration of AF before surgery. There is a slight decrease in
success rate as you go into the larger size of atrium, but 16% of pa-
tients had left atrial size>6 cm. So we are not talking about giant
atria. I don’t think we have enough evidence to support left atrial
reduction, we don’t have time to discuss it here, but I am not doing
left atrium reduction surgery besides cutting out the left atrial
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